

Jason K Sa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3952349/publications.pdf>

Version: 2024-02-01

46
papers

2,204
citations

361296

20
h-index

243529

44
g-index

50
all docs

50
docs citations

50
times ranked

4092
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program. <i>Cancer Discovery</i> , 2022, 12, 938-948.	7.7	19
2	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	3.6	68
3	Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 270-280.	0.6	5
4	Recapitulated Crosstalk between Cerebral Metastatic Lung Cancer Cells and Brain Perivascular Tumor Microenvironment in a Microfluidic Co-culture Chip. <i>Advanced Science</i> , 2022, 9, .	5.6	12
5	Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (<scp>KGOG</scp>) Tj ETQq1 201784314 rgBT /Ove	10.7	14
6	Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. <i>Cell Death and Disease</i> , 2021, 12, 374.	2.7	15
7	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instabilityâ€“High Gastric Cancer. <i>Cancer Discovery</i> , 2021, 11, 2168-2185.	7.7	105
8	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. <i>Genome Medicine</i> , 2021, 13, 11.	3.6	17
9	Modulation of Nogo receptor 1 expression orchestrates myelin-associated infiltration of glioblastoma. <i>Brain</i> , 2021, 144, 636-654.	3.7	16
10	Effects of Long-Term In Vitro Expansion on Genetic Stability and Tumor Formation Capacity of Stem Cells. <i>Stem Cell Reviews and Reports</i> , 2021, , 1.	1.7	1
11	MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. <i>Nature Communications</i> , 2020, 11, 3883.	5.8	110
12	Ethnic delineation of primary glioblastoma genome. <i>Cancer Medicine</i> , 2020, 9, 7352-7359.	1.3	6
13	Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. <i>Genome Biology</i> , 2020, 21, 216.	3.8	73
14	ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. <i>Nature Communications</i> , 2020, 11, 2978.	5.8	78
15	Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 4904.	1.6	10
16	Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. <i>Nature Communications</i> , 2020, 11, 3288.	5.8	44
17	Multi-Habitat Radiomics Unravels Distinct Phenotypic Subtypes of Glioblastoma with Clinical and Genomic Significance. <i>Cancers</i> , 2020, 12, 1707.	1.7	18
18	A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring<i>HRAS</i> Mutations. <i>Clinical Cancer Research</i> , 2020, 26, 5113-5119.	3.2	27

#	ARTICLE	IF	CITATIONS
19	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020, 12, 17.	3.6	20
20	Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas. <i>Cancer Research and Treatment</i> , 2020, 52, 41-50.	1.3	14
21	Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 47-58.	0.6	28
22	Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 222-233.	0.6	12
23	The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival. <i>Communications Biology</i> , 2019, 2, 135.	2.0	49
24	PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1120-1134.	4.2	27
25	Ly6G+ inflammatory cells enable the conversion of cancer cells to cancer stem cells in an irradiated glioblastoma model. <i>Cell Death and Differentiation</i> , 2019, 26, 2139-2156.	5.0	25
26	GENE-12. ANALYSIS OF FAILURE PATTERNS IN MALIGNANT GLIOMA: EXPLORING THE GENETIC LANDSCAPE OF PATTERN OF FAILURE. <i>Neuro-Oncology</i> , 2019, 21, vi100-vi100.	0.6	0
27	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. <i>Frontiers in Oncology</i> , 2019, 9, 1327.	1.3	5
28	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. <i>Genome Biology</i> , 2019, 20, 253.	3.8	16
29	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	13.7	320
30	Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations. <i>International Journal of Cancer</i> , 2019, 144, 3023-3030.	2.3	16
31	Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization. <i>Medical Oncology</i> , 2018, 35, 60.	1.2	14
32	Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma. <i>Cancer Medicine</i> , 2018, 7, 1774-1783.	1.3	5
33	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018, 20, 873-884.	0.6	119
34	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. <i>Nature Genetics</i> , 2018, 50, 1399-1411.	9.4	145
35	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. <i>Cell</i> , 2018, 175, 1665-1678.e18.	13.5	250
36	A tension-mediated glycofocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma. <i>Nature Cell Biology</i> , 2018, 20, 1203-1214.	4.6	103

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics, Biodistribution, and Toxicity Evaluation of Anti-SEMA3A (F11) in In Vivo Models. <i>Anticancer Research</i> , 2018, 38, 2803-2810.	0.5	2
38	Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth. <i>Cancer Research and Treatment</i> , 2018, 50, 1009-1022.	1.3	21
39	Spatiotemporal genomic architecture informs precision oncology in glioblastoma. <i>Nature Genetics</i> , 2017, 49, 594-599.	9.4	223
40	Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody. <i>Biochemical and Biophysical Research Communications</i> , 2017, 494, 409-415.	1.0	3
41	Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBP β Signaling. <i>Cancer Research</i> , 2017, 77, 4973-4984.	0.4	68
42	Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1968.	1.8	12
43	Genomic and transcriptomic characterization of skull base chordoma. <i>Oncotarget</i> , 2017, 8, 1321-1328.	0.8	17
44	Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma. <i>International Journal of Oncology</i> , 2016, 48, 1053-1062.	1.4	9
45	Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy. <i>Oncotarget</i> , 2016, 7, 29400-29411.	0.8	30
46	<i>In vivo</i> RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma. <i>Oncotarget</i> , 2015, 6, 20145-20159.	0.8	23